Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML

[1]  J. Piette,et al.  Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. , 2016, Rheumatology.

[2]  J. Mairesse,et al.  Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis , 2016, British journal of haematology.

[3]  B. Esterni,et al.  Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities , 2015, American journal of hematology.

[4]  S. Scholl,et al.  Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review , 2014, European journal of haematology.

[5]  P. Chevallier,et al.  Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  L. Rink,et al.  Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation. , 2014, Immunobiology.

[7]  M. Bagot,et al.  Neutrophilic dermatoses as systemic diseases. , 2014, Clinics in dermatology.

[8]  Pierre Fenaux,et al.  Inflammatory Arthritis in Patients With Myelodysplastic Syndromes , 2014, Medicine.

[9]  P. Fenaux,et al.  Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? , 2013, Best practice & research. Clinical haematology.

[10]  C. Nakaseko,et al.  Successful treatment by azacitidine therapy of intestinal Behçet’s disease associated with myelodysplastic syndrome , 2013, International Journal of Hematology.

[11]  M. Voso,et al.  High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study , 2013, Leukemia & lymphoma.

[12]  Hiroaki TanakaNaomi,et al.  Successful treatment by azacitidine therapy of intestinal Behcet's disease associated with myelodysplastic syndrome , 2013 .

[13]  P. Vyas,et al.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.

[14]  D. Albert,et al.  Rheumatologic manifestations in myelodysplastic syndrome. , 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[15]  F. Atem,et al.  Activity of azacitidine in chronic myelomonocytic leukemia , 2011, Cancer.

[16]  Sophie Park,et al.  The autoimmune manifestations associated with myelodysplastic syndrome respond to 5‐azacytidine: a report on three cases , 2011, British journal of haematology.

[17]  P. Wallace,et al.  Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. , 2011, Leukemia research.

[18]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[19]  Y. Shoenfeld,et al.  Diagnostic criteria in autoimmune diseases , 2008 .

[20]  J. Salisbury,et al.  Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5‐azacytidine , 2007, The British journal of dermatology.

[21]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.